We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally
Read MoreHide Full Article
AcelRx Pharmaceuticals, Inc. announced that the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee has voted (10-3) in favor of Dsuvia, recommending an approval for it. The company is looking to get Dsuvia tablets (30 mcg) approved for treating moderate-to-severe acute pain in medically supervised settings for adult patients.
Although the FDA is not bound by the Advisory Committee's acknowledgement, it will still contemplate its positive recommendation while taking a decision. The FDA has set an action date of Nov 3, 2018.
Shares of the AcelRx were up more than 10% following this news on Friday. In fact, the stock has skyrocketed 96.6% so far this year against the industry’s decline of 4%.
The safety and efficacy data for Dsuvia was taken from two randomized, placebo-controlled studies with (n=261) patients and two open-label, single-arm studies with (n=216) patients. Data from both the studies showed that Dsuvia was well-tolerated and achieved desirable results in patients of different ages and body mass index (BMIs) as a non-invasive analgesic treatment option for managing moderate-to-severe acute pain.
Dsuvia is a sufentanil sublingual tablet and comes as a pre-filled applicator, intended to treat pain in multiple settings such as injury, ambulatory surgery or to post-operative patients.
We remind investors that in October 2017, the FDA issued a complete response letter (“CRL”) to Dsuvia for the same indication. However, this May, AcelRx resubmitted its new drug application ("NDA") for Dsuvia and the regulatory body accepted the NDA in the same month.
In June 2018, the European Commission granted a marketing approval to Dsuvia (known as Dzuveo outside the United States) for a similar inidication.
Zalviso (15 mcg) is another product of AcelRx, approved in Europe and is in late stage development in the United States.
Caladrius’ loss per share estimates has narrowed 5.7% for 2018 and 1.6% for 2019 over the past 60 days. The stock has surged 41.3% year to date.
United Therapeutics’ earnings estimates have been revised 3.6% upward for 2018 and 2.3% for 2019 over the past 60 days.
Genmab’s earnings estimates have moved 1.8% north for 2018 and 11.8% for 2019 over the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally
AcelRx Pharmaceuticals, Inc. announced that the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee has voted (10-3) in favor of Dsuvia, recommending an approval for it. The company is looking to get Dsuvia tablets (30 mcg) approved for treating moderate-to-severe acute pain in medically supervised settings for adult patients.
Although the FDA is not bound by the Advisory Committee's acknowledgement, it will still contemplate its positive recommendation while taking a decision. The FDA has set an action date of Nov 3, 2018.
Shares of the AcelRx were up more than 10% following this news on Friday. In fact, the stock has skyrocketed 96.6% so far this year against the industry’s decline of 4%.
The safety and efficacy data for Dsuvia was taken from two randomized, placebo-controlled studies with (n=261) patients and two open-label, single-arm studies with (n=216) patients. Data from both the studies showed that Dsuvia was well-tolerated and achieved desirable results in patients of different ages and body mass index (BMIs) as a non-invasive analgesic treatment option for managing moderate-to-severe acute pain.
Dsuvia is a sufentanil sublingual tablet and comes as a pre-filled applicator, intended to treat pain in multiple settings such as injury, ambulatory surgery or to post-operative patients.
We remind investors that in October 2017, the FDA issued a complete response letter (“CRL”) to Dsuvia for the same indication. However, this May, AcelRx resubmitted its new drug application ("NDA") for Dsuvia and the regulatory body accepted the NDA in the same month.
In June 2018, the European Commission granted a marketing approval to Dsuvia (known as Dzuveo outside the United States) for a similar inidication.
Zalviso (15 mcg) is another product of AcelRx, approved in Europe and is in late stage development in the United States.
Zacks Rank & Stocks to Consider
AcelRx currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Caladrius Biosciences, Inc. , United Therapeutics Corporation (UTHR - Free Report) and Genmab A/S (GNMSF - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Caladrius’ loss per share estimates has narrowed 5.7% for 2018 and 1.6% for 2019 over the past 60 days. The stock has surged 41.3% year to date.
United Therapeutics’ earnings estimates have been revised 3.6% upward for 2018 and 2.3% for 2019 over the past 60 days.
Genmab’s earnings estimates have moved 1.8% north for 2018 and 11.8% for 2019 over the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>